ArticleInfection and immunity2012
The Vsa shield of Mycoplasma pulmonis is antiphagocytic.
Article in Infection and immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Exploring the pangenome of Mycoplasma hyorhinis in search of potential virulence markers.Scientific reports · 2025Article
- Unveiling the stealthy tactics: mycoplasma's immune evasion strategies.Frontiers in cellular and infection microbiology · 2023Review
- Serum Resistance ofPathogens (Basel, Switzerland) · 2022Article
- Sheep Infection Trials with 'Phase-Locked' Vpma Expression Variants ofMicroorganisms · 2022Article
- Upregulation of PD-L1 Expression by Prostaglandin EFrontiers in veterinary science · 2020Article
- Mycoplasma hyopneumoniae evades phagocytic uptake by porcine alveolar macrophages in vitro.Veterinary research · 2019Article
- Vpma phase variation is important for survival and persistence of Mycoplasma agalactiae in the immunocompetent host.PLoS pathogens · 2017Article
- Article
- Rhamnose biosynthesis in mycoplasmas requires precursor glycans larger than monosaccharide.Molecular microbiology · 2013Article
- CpG underrepresentation and the bacterial CpG-specific DNA methyltransferase M.MpeI.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- EPS-I polysaccharide protects Mycoplasma pulmonis from phagocytosis.FEMS microbiology letters · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The infection of mice with Mycoplasma pulmonis is a model for studying chronic mycoplasmal respiratory disease. Many in vivo and in vitro studies have used the organism to gain a better understanding of host-pathogen interactions in chronic respiratory infection. The organism's Vsa proteins contain an extensive tandem repeat region. The length of the tandem repeat unit varies from as few as 11 amino acids to as many as 19. The number of tandem repeats can be as high as 60. The number of repeats varies at a high frequency due to slipped-strand mispairing events that occur during DNA replication. When the number of repeats is high, e.g., 40, the mycoplasma is resistant to lysis by complement but does not form a robust biofilm. When the number of repeats is low, e.g., 5, the mycoplasma is killed by complement when the cells are dispersed but has the capacity to form a biofilm that resists complement. Here, we examine the role of the Vsa proteins in the avoidance of phagocytosis and find that cells producing a protein with many tandem repeats are relatively resistant to killing by macrophages. These results may be pertinent to understanding the functions of similar proteins that have extensive repeat regions in other microbes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.